Navigation Links
Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
Date:10/23/2007

SAN FRANCISCO -- Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.

Findings from this Phase 2 Consortium (P2C) clinical trial were presented by the studys primary investigator, Keith Bible, M.D., Ph.D., at the Molecular Targets and Cancer Therapeutics International Conference, a jointly-sponsored symposium of the American Association for Cancer Research, National Cancer Institute and the European Organization for Research and Treatment of Cancer.

We are encouraged by the interim results of this trial, says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. Platinum-resistant ovarian cancer responds poorly to traditional therapies, and weve been working toward developing more effective treatments for this disease. This combination looks very promising.

More than 22,400 women in the United States will be diagnosed with ovarian cancer this year, according to the American Cancer Society, and nearly 15,300 women will die from it. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents).

In this study, the researchers evaluated a combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers. The researchers found in earlier preclinical studies that flavopiridol significantly boosts the anti-cancer effects of cisplatin, and later conducted a Phase I clinical trial to pilot the combination in patients (KC Bible et al, Clinical Cancer Research, 11:5935, 2005). The present Phase II trial was designed to extend this work and better determine this therapys effectiveness against platinum-resistant cancers.

Dr. Bible and his co-investigators treated 18 platinum-resistant Caucasian patients with this combination therapy. Of the 18 patients, all of whom were receiving the therapy as a second-line treatment after disease progression, one patient experienced complete response (all signs of cancer gone) and five other patients experienced partial responses (tumor regression). The 33 percent overall response rate (6 of 18 patients) is about twice as high as seen using traditional chemotherapy regimens.

The researchers also offered the combination therapy to five patients with platinum-sensitive (original therapy resulted in no recurrence for greater than 12 months) ovarian cancer. Of these women, one experienced complete response and three others partial response.

We now need to expand this trial to validate these interim results in additional patients, says Dr. Bible. Were also looking for ways to further boost the anti-cancer effects of the combination, in hopes of developing even more effective approaches to ovarian cancer.


'/>"/>

Contact: Amy Tieder
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. How do patients benefit of clinical trials
3. Magnetic resonance angiography in clinical medicine
4. Clinical trials need to be more frank
5. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
8. Clinical Comparisons Between ADHD Drugs Are Less
9. Specialized Clinics For Manipurs AIDS Patients
10. Outsourcing clinical trials to India
11. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The Dog Who ... who lives his life to the fullest, as God intended. “The Adventures of Joey, ... a mother and grandmother pursuing her passion for writing, especially about truth and human ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... Montclair, NJ (PRWEB) , ... March 23, 2017 ... ... the Renaissance Oklahoma City Convention Center at 10 North Broadway Avenue, will be ... 6.0 hours of relevant, practical instruction in the management of chronic pain. , ...
(Date:3/23/2017)... , ... March 23, 2017 , ... 82% of adults are unaware of the dangers ... not brush their teeth the minimum two times a day that dentists recommend. The ramifications ... 51 million hours of school and adults missing 164 million hours of work each year ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 The key ... population, increasing diabetic population, accelerating economic growth and increasing healthcare ... industry are higher life expectancy of ESRD patients, rising demand ... markets. However, the expansion of the market is hindered by ... ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a ... an end-to-end supply chain management firm with expertise serving ... Product Solutions Rick Zaffarano was named a ... the Supply Chain by the only publication exclusively dedicated ... food supply chain. "Rick has brought to ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
Breaking Medicine Technology: